Business
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine
Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and mor
About this update from Ion Beam Applications Sa
[{"type":"image","alt":"IBA SA","displaySize":"","headline":null,"caption":"IBA SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":85,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z4qZvB1n65el3DgzVQJgKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85}},"lazy":false},{"type":"text","content":"Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium.","length":260,"tagName":"p"},{"type":"text","content":"This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient therapy.","length":270,"tagName":"p"},{"type":"text","content":"The combination of IBA cyclotron leadership with ORA’s cutting-edge technology provides one of the most competitive integrated solutions for hospitals and global radiopharmacy networks looking for high productivity and access to labelling of advanced radioisotopes.","length":265,"tagName":"p"},{"type":"text","content":"This acquisition complements IBA’s existing nuclear medicine strategic initiatives including the co-founding of PanTera for the production of Ac-225, and the shaping of the Accelerate.EU program, as well as the ongoing collaboration with Framatome to explore opportunities in the production of At-211. It is an additional step for IBA on its journey to bring innovation in care to patients and to accelerate the translation of innovative nuclear medicine solutions from bench to bedside.","length":487,"tagName":"p"},{"type":"text","content":"The transaction, for a total consideration of € 15-20 million on a cash-free, debt-free basis, is immediately accretive to IBA Technologies’ revenue and EBITDA and is expected to generate revenue synergies. Financed through IBA’s own funds and existing credit facilities, the acquisition will not have material impact on IBA’s 2025 financial guidance or mid-term o...